Analysis of chemoresistance characteristics and prognostic relevance of postoperative gemcitabine adjuvant chemotherapy in pancreatic cancer
Cancer Medicine · 2024
DOI: 10.1002/cam4.7229 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Jiaqiang Ren und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Gemcitabine, Pancreatic Neoplasms, Deoxycytidine, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Science and Technology of Shaanxi Province, China, the National Natural Science Foundation of China, the First Affiliated Hospital of Xi'an Jiaotong University.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Aim
To investigate the relationship between chemoresistance in pancreatic cancer patients receiving postoperative gemcitabine adjuvant therapy and specific clinical/pathological characteristics, as well as its impact on patient prognosis.
Methods
From June 2018 to June 2021, clinical and pathological data of 148 pancreatic cancer patients were collected, and 101 patients were followed up for tumor recurrence/metastasis and survival status. The correlation between chemoresistance and specific clinical/pathological characteristics or patient prognosis was retrospectively analyzed.
Results
Of the 148 patients, 78 were in the chemoresistance group and 70 in the non‐chemoresistance group. Univariate analysis showed that the development of chemoresistance may be related to patient age, combined diabetes, preoperative CA19‐9 level, tumor size, AJCC stage, vascular invasion, and positive lymph node ratio. Furthermore, subsequent multivariate analysis incorporating these variables indicated that tumor size may be a key factor influencing chemoresistance ( p < 0.001, OR = 1.584). Log‐rank test showed patients in the chemoresistance group had worse overall survival (OS) (HR = 2.102, p = 0.018) and progression free survival (PFS) (HR = 3.208, p = 0.002) than patients in the non‐chemoresistance group; and patients with smaller size tumors (diameter ≤3 cm) had significantly better OS (HR = 2.923, p < 0.001) and PFS (HR = 2.930, p = 0.003) than those with larger size tumors (diameter >3 cm).
Conclusions
Patients with pancreatic cancer receiving postoperative gemcitabine adjuvant therapy are more likely to develop chemoresistance when their tumor sizes are larger (diameter >3 cm). Development of chemoresistance exacerbates the prognosis of patients with pancreatic cancer, and larger tumor size is also a risk factor for poor prognosis in these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
- School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China.
Förderung
- Department of Science and Technology of Shaanxi Province, China
- the National Natural Science Foundation of China
- the First Affiliated Hospital of Xi'an Jiaotong University
- National Natural Science Foundation of China
Zitieren
APA
Ren, J., Wu, S., Su, T., Ding, J., Chen, F., Li, J., Wang, Z., Han, L., & Wu, Z. (2024). Analysis of chemoresistance characteristics and prognostic relevance of postoperative gemcitabine adjuvant chemotherapy in pancreatic cancer. Cancer Medicine. https://doi.org/10.1002/cam4.7229
Vancouver
Ren J, Wu S, Su T, Ding J, Chen F, Li J, et al. Analysis of chemoresistance characteristics and prognostic relevance of postoperative gemcitabine adjuvant chemotherapy in pancreatic cancer. Cancer Medicine. 2024. doi:10.1002/cam4.7229
BibTeX
@article{Ren2024,
author = {Ren, Jiaqiang and Wu, Shuai and Su, Tong and Ding, Jiachun and Chen, Fan and Li, Jie and Wang, Zheng and Han, Liang and Wu, Zheng},
title = {Analysis of chemoresistance characteristics and prognostic relevance of postoperative gemcitabine adjuvant chemotherapy in pancreatic cancer},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7229}
}
EUVIMED